Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Adjunctive IgM-enriched Immunoglobulin Therapy With a Personalized Dose Based on Serum IgM-titers vs. Standard Dose in Patients With Septic Shock. A Multicenter, Interventional, Randomized, Single-blinded, Two Arms Trial.

NCT04182737 is registered in ClinicalTrials.gov with Massimo Girardis as lead sponsor.

NCT NCT04182737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04182737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Adjunctive IgM-enriched Immunoglobulin Therapy With a Personalized Dose Based on Serum IgM-titers vs. Standard Dose in Patients With Septic Shock. A Multicenter, Interventional, Randomized, Single-blinded, Two Arms Trial.
Lead sponsor
Massimo Girardis
Phase
Phase 3
Overall status
Unknown status
Start date
May 1, 2020
Completion date
March 31, 2022
Enrollment
356 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypoglobulinemia, sepsis, shock, septic